EUVIMEDEUVIMED entdecken
Crossref

Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma

Sarah Fleming, Dina Gifkins, Helaine E Resnick, Waleed Shalaby, Philip Rosenberg, Chris Gaj, Vittorio Maio, Albert Crawford, Grace Lu-Yao, Jianjun Gao, Arlene Siefker-Radtke

Clinical Genitourinary Cancer · 2024

DOI: 10.1016/j.clgc.2024.02.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Genitourinary Cancer, 2024. Verfasst von Sarah Fleming und 10 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Global Services, Titusville, NJ. Electronic address: sflemin@its.jnj.com. Hauptthemen laut MEDLINE: Receptors, Fibroblast Growth Factor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Janssen Pharmaceutica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Evidence is limited on whether fibroblast growth factor receptor gene alterations (FGFRalt) impact clinical outcomes in patients with locally advanced or metastatic urothelial cancer (mUC). This study evaluated progression-free survival (PFS) in patients with mUC based on FGFRalt status in the first-line setting (1L). PATIENTS AND METHODS: Data on mUC patients were retrieved via convenience sampling of oncologists/urologists surveyed between August and September 2020 who treated at least 1 FGFRalt patient between July 2017 and June 2019. The questionnaire included information on patient demographics, FGFR status, treatment, and clinical and radiographic measures of progression. Primary endpoint was time from metastatic diagnosis to disease progression from initial treatment for FGFRalt and FGFRwt (wild-type) mUC. Cox proportional hazards models quantified adjusted risk of FGFR status relating to PFS. RESULTS: A total of 414 patients were analyzed. Mean age was 64.5 years, 73.9% were male, and 52.7% had an FGFRalt. Among FGFRalt, 47.2% received chemotherapy, 27.5% immune checkpoint inhibition (ICI), 11.5% chemotherapy+ICI, and 13.8% other treatments in 1L. FGFR status did not influence PFS from time of mUC diagnosis or among 224 stratified patients receiving either chemotherapy or chemotherapy+ICI. However, among 97 patients with an FGFRalt receiving 1L ICI therapy only, adjusted risk of progression was twice that of FGFRwt (HR: 2.12; 95% CI: 1.13-4.00). CONCLUSION: Although FGFRalt did not predict outcomes in the overall cohort, for patients treated with 1L ICI, FGFRalt had significantly higher rates of progression than FGFRwt patients. Further validation is needed to determine whether FGFRalt has a decreased benefit from ICI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Fibroblast Growth FactorHumansMaleFemaleMiddle AgedAgedPrognosisCarcinoma, Transitional CellProgression-Free SurvivalUrinary Bladder NeoplasmsMutationRetrospective StudiesImmune Checkpoint InhibitorsDisease Progression

Stichwörter der Autor:innen

Bladder cancerEpidemiologyGenetic aberrationReal-world evidence,Survival

Substanzen

Receptors, Fibroblast Growth FactorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Janssen Global Services, Titusville, NJ. Electronic address: sflemin@its.jnj.com.
  • Janssen Global Services, Titusville, NJ.
  • Resnick, Chodorow & Associates, LLC, Silver Spring, MD.
  • Janssen Scientific Affairs, LLC, Horsham, PA.
  • Research Partnership, Horsham, PA.
  • College of Population Health, Thomas Jefferson University, PA.

Förderung

  • Janssen Pharmaceutica

Zitieren

APA

Fleming, S., Gifkins, D., Resnick, H. E., Shalaby, W., Rosenberg, P., Gaj, C., Maio, V., Crawford, A., Lu-Yao, G., Gao, J., & Siefker-Radtke, A. (2024). Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2024.02.005

Vancouver

Fleming S, Gifkins D, Resnick HE, Shalaby W, Rosenberg P, Gaj C, et al. Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer. 2024. doi:10.1016/j.clgc.2024.02.005

BibTeX
@article{Fleming2024,
  author = {Fleming, Sarah and Gifkins, Dina and Resnick, Helaine E and Shalaby, Waleed and Rosenberg, Philip and Gaj, Chris and Maio, Vittorio and Crawford, Albert and Lu-Yao, Grace and Gao, Jianjun and Siefker-Radtke, Arlene},
  title = {Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma},
  journal = {Clinical Genitourinary Cancer},
  year = {2024},
  doi = {10.1016/j.clgc.2024.02.005}
}
Kostenlos starten →